This is a type of cancer that starts in the tissues around joints, like tendons and bursae. It's called a sarcoma, which is a type of cancer that starts in connective tissues. It can happen in the legs or other areas.
Every report comes from a Lived member, sent anonymously.
Have you had Surgery for Synovial Sarcoma?
Synovial sarcoma is a rare cancer of the body's soft tissues, the muscles, tendons, ligaments and other tissues that connect and support the body. It most often forms in an arm or leg, frequently near a joint such as the knee, ankle or wrist, but it can also start in the trunk, abdomen, lung or head and neck. Despite its name, it does not grow from the lining of the joint (the synovium). Synovial sarcoma makes up roughly 5 to 10 percent of soft tissue sarcomas, and about 1,000 people are diagnosed with it in the United States each year. Unlike most sarcomas, it often affects adolescents and young adults: about a third of people are diagnosed before age 30, and it is one of the more common soft tissue sarcomas in children. It often grows slowly. Many people first notice a lump, but pain or stiffness near a joint can come before any visible swelling, so it is sometimes treated at first as tendonitis, bursitis or another harmless problem. Because it is a cancer that can spread, most often to the lungs, a timely diagnosis and treatment by an experienced sarcoma team matter.
Synovial sarcoma is driven by a specific change inside the tumor cells. Pieces of two chromosomes (X and 18) break and rejoin in the wrong places, fusing a gene called SS18 to one of the SSX genes. The fused gene makes an abnormal protein that drives the cancer's growth. This change is found in more than 95 percent of these tumors. The chromosome change arises in the tumor during a person's life. It is not inherited, and synovial sarcoma does not run in families. Researchers have not identified what triggers the break.
Assessment usually starts with imaging. An MRI shows the lump's size, depth and relationship to nearby nerves, blood vessels and bone, and X-rays, ultrasound or CT may add information. Imaging can raise suspicion of a sarcoma, but it cannot confirm one. A biopsy is the only way to make the diagnosis. Most often this is a core needle biopsy, often guided by imaging, in which a hollow needle removes small strips of tissue. The biopsy should come before any attempt to remove the lump, ideally at a center experienced with sarcoma. A lump cut out without that planning can leave cancer cells behind and make later surgery larger, and this kind of unplanned removal is linked to a worse outlook. There are more than 80 kinds of soft tissue sarcoma, so the sample is best examined by a pathologist experienced in sarcoma, who also tests for the SS18 gene fusion to confirm the diagnosis. Staging then checks whether the cancer has spread. A CT scan of the chest is standard because the lungs are the most common site of spread, and up to about 13 percent of people already have spread to distant sites when they are diagnosed. The stage combines the tumor's size, its grade (how abnormal the cells look and how quickly they appear to be dividing) and whether it has spread.
Treatment is planned by a team of sarcoma specialists in surgery, radiation and cancer medicine, and depends on the tumor's size, depth and location and whether it has spread. Taking part in a clinical trial is worth asking about at every stage of this rare cancer. For a tumor that has not spread, surgery is the main treatment. The aim is to remove the tumor with a rim of healthy tissue around it (a clear or negative margin), because clear margins lower the chance of the cancer returning in the same place and are linked to better survival. Amputation was once common, but today most people with a tumor in an arm or leg have limb-sparing surgery that keeps a working limb. Radiation is often added for larger or deeper tumors, or when the tumor sits so close to a major nerve, blood vessel or bone that a wide margin is not possible. Given before surgery, it raises the chance of wound-healing problems; given after, it more often leads to lasting scarring and joint stiffness. Which timing makes sense depends on the tumor's location and the surgical plan. Synovial sarcoma responds to chemotherapy more often than most soft tissue sarcomas. The usual drugs are ifosfamide and doxorubicin, given around the time of surgery for higher-risk tumors, or as the main treatment when the cancer has spread or cannot be removed. In children and adolescents with larger or higher-risk tumors, chemotherapy is a standard part of treatment. In adults, studies disagree about how much it improves survival, so the decision weighs the tumor's risk features against the treatment's considerable side effects. When the cancer has spread or returned, options also include surgery to remove limited spread in the lungs for some people, and pazopanib (Votrient), a kinase inhibitor tablet approved for advanced soft tissue sarcoma after chemotherapy. Pazopanib can delay further growth for a time and requires regular liver blood tests. Afamitresgene autoleucel (Tecelra) is a one-time cell therapy approved in the United States for synovial sarcoma that has spread or cannot be removed and has already been treated with chemotherapy, in people 12 and older. A person's own T cells (a type of immune cell) are collected, engineered in a lab to recognize a protein called MAGE-A4 in the tumor cells, and infused back after a short course of chemotherapy. It is only an option for people with certain inherited tissue types (specific HLA-A*02 types, found by a blood test) whose tumor tests positive for MAGE-A4, so many people do not qualify. In the trial that led to approval, tumors shrank substantially in about 4 in 10 people, and some responses have lasted for years. Most people develop cytokine release syndrome, an immune reaction that causes fever and can lower blood pressure, and blood counts can stay low for weeks. People are watched daily at the treatment facility for at least a week, need to stay close to it for at least two weeks and should not drive during that time. Fever, chills, dizziness, a racing or irregular heartbeat or shortness of breath in the weeks after infusion needs immediate medical attention.
Outlook varies widely. In recent studies, about 60 to 75 percent of people are alive five years after diagnosis, and children and adolescents do better than adults (in one large registry study, about 83 percent compared with 62 percent). Smaller tumors, clear surgical margins, a location in an arm or leg and younger age are linked to better outcomes; larger tumors, tumors in the trunk and spread at diagnosis are linked to worse ones. Because the disease is rare, these figures come from small groups treated in the past and cannot predict any one person's course. Recovery after surgery and radiation takes time, and lasting stiffness in a nearby joint is a recognized after-effect of radiation. How much the treated limb is affected depends on how much tissue had to be removed and where. Synovial sarcoma is unusual in how late it can come back. Most soft tissue sarcomas that return do so within about two years, but synovial sarcoma can reappear at the original site or in the lungs five, ten or even fifteen years later. Follow-up therefore usually continues for many years, with examinations and imaging of the original site and the chest, most often in the first few years and less often after that.
See a clinician about a lump or swelling that persists or keeps growing, or about joint or limb pain or stiffness that does not improve as expected, including in teenagers and young adults. If imaging suggests a sarcoma is possible, ask to be seen at a sarcoma center before anyone removes the lump. After treatment, contact the care team promptly about a new lump at or near the treated area, a cough or shortness of breath that does not clear up, or new pain that persists. These often have ordinary causes, but in synovial sarcoma they can also signal a return of the cancer, even many years later.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Synovial Sarcoma is like, what's helped you, or ask the community a question.